SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor and medical conferences, including presentations featuring VIZZ at Academy 2025 presented by the ...

Core Viewpoint - Immuneering Corporation has announced a clinical supply agreement with Eli Lilly for the evaluation of atebimetinib in combination with olomorasib in a Phase 2 trial targeting advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations [1][2] Group 1: Clinical Development - The agreement supports the evaluation of Immuneering's lead product candidate, atebimetinib, a novel dual MEK inhibitor, in combination with olomorasib [1] - Immuneering is also evaluating atebimetinib in combination with Regeneron's anti-PD-1 therapy Libtayo in advanced NSCLC patients [1] - The combination aims to provide a vertical blockade of the RAS-MAPK pathway, potentially improving treatment outcomes in patients with limited options [3] Group 2: Product and Pipeline - Immuneering maintains global development and commercialization rights to atebimetinib [4] - The company is developing Deep Cyclic Inhibitors, with atebimetinib designed to improve durability and tolerability for MAPK pathway-driven tumors [5] - Atebimetinib is currently in a Phase 2a trial for advanced solid tumors, including pancreatic cancer [5]

Core Insights - Amarin Corporation will present new data on icosapent ethyl (IPE) at the European Society of Cardiology (ESC) Congress 2025, highlighting its cardioprotective effects [1][2] - The data will focus on IPE's role in reducing cardiovascular risk through various mechanisms, including inflammation and lipoprotein oxidation [2][3] Presentation Highlights - New analyses from the REDUCE-IT trial will evaluate the clinical benefits of IPE, including its impact on hospitalization risk and duration [2][3] - Mechanistic studies will explore the effects of eicosapentaenoic acid (EPA) on inflammasome activation and pro-inflammatory protein expression in endothelial cells [2][3] Educational Initiatives - Amarin will support educational programming addressing residual cardiovascular risk, featuring presentations by medical and scientific leaders in Europe [3][5] Symposium and Abstracts - Moderated poster presentations will include topics such as the reduction of cardiovascular disease risk in cardiovascular-kidney-metabolic syndrome and the impact of IPE across different apolipoprotein B and triglyceride levels [4][7] - Oral presentations will cover the effects of IPE on hospitalization risks and the modulation of inflammasome activation in macrophages [7] Company Overview - Amarin is focused on advancing cardiovascular disease management and understanding residual cardiovascular risk beyond traditional therapies [8] - The company has a global presence with offices in the United States, Ireland, Switzerland, and partnerships worldwide [8] Product Information - VASCEPA (icosapent ethyl) is the first FDA-approved treatment solely comprising IPE, aimed at high-risk patients with persistent cardiovascular risk despite statin therapy [9] - Since its launch, VASCEPA has been prescribed over 25 million times and is covered by most major medical insurance plans [9]

Safety and Pharmacokinetic Data Support Dosing ofART26.12 in Fed or Fasted Conditions Completion of Positive Single Ascending Dose Study with a Preliminary Food Effect Assessment Advances ART26.12 Toward Multiple Ascending Dose Trial SOLANA BEACH, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological co ...

Core Viewpoint - MannKind Corporation has signed a definitive merger agreement to acquire scPharmaceuticals Inc, marking a strategic expansion into cardiorenal medicine and enhancing its cardiometabolic business alongside its orphan lung division [1][2]. Strategic and Financial Benefits - The acquisition is expected to diversify and accelerate double-digit revenue growth, particularly through FUROSCIX, which addresses significant unmet needs in chronic heart failure and chronic kidney disease [6][7]. - MannKind will pay an upfront cash of $5.35 per share, representing a 36% premium to scPharmaceuticals' 90 trading day VWAP, with total consideration potentially reaching $6.35 per share [6][9]. - The total equity value of the transaction is approximately $303 million, with a total deal value of up to $360 million, expected to close in Q4 2025 [9]. Commercial Momentum - scPharmaceuticals has shown strong commercial momentum, with net sales of $27.8 million for the first half of 2025, reflecting a 96% year-over-year increase [3]. - The FUROSCIX ReadyFlow Autoinjector is on track for a supplemental New Drug Application submission in Q3 2025, which could significantly reduce treatment time for patients [3][6]. Revenue Diversification - The combined company will have a stronger revenue base with three commercial assets: Afrezza, FUROSCIX, and V-Go, leading to an annualized run rate of over $370 million based on Q2 2025 results [7]. - MannKind anticipates double-digit annual growth from its commercial products, supported by upcoming product launches and indication expansions [7][8]. Integration and Growth Opportunities - The integration of scPharmaceuticals' established commercial and medical capabilities into MannKind's infrastructure is expected to unlock meaningful growth opportunities [6][8]. - MannKind's existing strengths in endocrinology and scPharmaceuticals' expertise in cardiovascular care will enhance the market opportunity for FUROSCIX in chronic kidney disease [8].

Core Insights - Johnson & Johnson's stock has increased over 23% year-to-date, indicating strong investor confidence despite ongoing legal challenges [1] - The strategic separation of its consumer health division has transformed Johnson & Johnson into a more agile company focused on high-margin, high-growth sectors [2][3] - The company is now dedicated to innovative medicine and medical technology, moving away from legacy lawsuit risks towards a clearer growth path [3] Financial Performance - The 2023 spinoff of the consumer health business, now Kenvue, has allowed Johnson & Johnson to focus on pharmaceuticals and MedTech, enhancing shareholder value [4] - In Q2 2025, total revenues reached $23.74 billion, with Innovative Medicine contributing $15.20 billion and MedTech $8.54 billion [5] - Management raised its full-year sales guidance by $2 billion, reflecting a sharpened focus on high-return opportunities [6] Pharmaceutical Division Strength - Johnson & Johnson's pharmaceutical division is robust, with a strong portfolio of drugs offsetting anticipated challenges [7] - The oncology franchise saw a remarkable 22.3% operational sales growth in Q2, driven by successful products like Darzalex and Carvykti [12] - The company is managing the transition of Stelara effectively, with its successor Tremfya growing 30.1% [12] MedTech Division Growth - The MedTech division achieved 6.1% operational growth in Q2, with the cardiovascular business expanding by 22% [9] - Recent acquisitions, such as Abiomed and Shockwave Medical, are exceeding expectations and establishing Johnson & Johnson as a leader in high-growth cardiovascular markets [10] Future Growth Potential - Johnson & Johnson's late-stage pipeline indicates a clear path to future revenue, with the FDA granting Priority Review for TAR-200 and a recent application for icotrokinra [12] - The company's M&A strategy adds diversification and financial strength, supporting long-term liabilities while maintaining innovation [11] Investment Appeal - Johnson & Johnson is trading at a forward P/E ratio of 16.88, offering a blend of growth potential and financial stability [13] - The company has a strong dividend history, with a yield of 2.91% and a sustainable payout ratio of 55.6% of earnings, indicating safety and room for growth [18]

Core Viewpoint - Voyageur Pharmaceuticals Ltd. is launching a U.S.-based iodine feasibility program aimed at establishing a vertically integrated production system for iodine-based contrast media drugs used in diagnostic imaging [1][3]. Group 1: Iodine Feasibility Program - The program will start with bench-scale testing of iodine-rich oilfield brine water to assess the technical and economic viability of iodine extraction [2]. - Voyageur has developed a proprietary manufacturing method called the "Streamline Process," which will be refined during the feasibility phase with third-party engineering experts [2]. - Upon successful testing, the next phase will evaluate the construction of a processing facility for iodine extraction and contrast media drug manufacturing [2]. Group 2: Strategic Goals - The initiative aligns with Voyageur's long-term strategy to vertically integrate the radiology contrast media supply chain from raw mineral extraction to final drug production in North America [3]. - The project addresses national security concerns regarding foreign reliance on the iodine supply chain, currently dominated by manufacturers in Europe and China [3]. - Voyageur aims to capture market share by providing a fully domestic, cost-efficient, and stable supply chain for iodine contrast media [4]. Group 3: Market Demand and Production Plans - According to WHO, there is a significant demand for IV iodinated contrast media, with 3.6 billion diagnostic exams conducted annually, including 350 million on children under 15 [4]. - Global demand for iodinated contrast media is expected to double in the next 10 years, highlighting the need for increased production capacity [4]. - Voyageur plans to scale iodine production to potentially 1,000 tonnes per year for long-term market supply [6]. Group 4: Government Engagement and Partnerships - Voyageur is engaging with U.S. government funding programs for critical minerals and domestic pharmaceutical manufacturing [5]. - The company is in discussions with global iodine contrast media companies and financial groups to support this initiative [5]. Group 5: Business Model and Market Position - Voyageur aims to become a key player in the barium and iodine contrast markets by producing its own active pharmaceutical ingredients (APIs) [7]. - The company plans to partner with established third-party GMP pharmaceutical manufacturers to validate its products by regulatory agencies worldwide [8]. - Voyageur owns a 100% interest in the Frances Creek barium sulphate project, which is expected to produce higher quality imaging products compared to current synthetic alternatives [9]. Group 6: Vision and Commitment - Voyageur's vision is to be the first vertically integrated company in the radiology contrast media drug market, controlling all primary input costs from raw material sourcing to final production [10]. - The company emphasizes responsible sourcing and manufacturing practices, encapsulated in its motto "From the Earth to the Bottle" [10].

一品红公告，全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于草酸 艾司西酞普兰滴剂的《药品注册证书》。草酸艾司西酞普兰滴剂适应症为：治疗抑郁症。治疗伴有或不 伴有广场恐怖症的惊恐障碍。公司获批的草酸艾司西酞普兰滴剂是以化学药品 3 类申报注册，视同通过 一致性评价。根据米内网数据，2024年艾司西酞普兰在中国城市和县级公立医院的销售规模约为18.8亿 元人民币。 ...

格隆汇8月25日丨马应龙(600993.SH)布，公司子公司江西马应龙美康药业有限公司（称"马应龙美康"） 收到国家药品监督管理局核准签发的盐酸奥洛他定滴眼液（称"该药品"）《药品注册证书》（证书编 号：2025S02553），盐酸奥洛他定滴眼液用于治疗过敏性结膜炎相关的眼痒。 ...

Core Viewpoint - The article highlights three healthcare stocks—Johnson & Johnson, Medtronic, and Omega Healthcare Investors—as attractive options for dividend-focused investors, emphasizing their strong dividend yields and resilience in the market [2][15]. Group 1: Johnson & Johnson - Johnson & Johnson is recognized as a Dividend King, having increased its dividend for over 50 consecutive years, with a current yield of 2.9%, significantly higher than the broader market's 1.2% and the healthcare sector's average of 1.8% [4][5]. - The company is a leader in pharmaceuticals and medical devices, with a strong global presence and robust R&D capabilities, which positions it well for future growth despite some near-term litigation concerns [5][6]. - A $500 investment would allow the purchase of approximately two shares, while $5,000 would enable the acquisition of 27 shares [6]. Group 2: Medtronic - Medtronic is approaching Dividend King status with 48 years of dividend increases and a current yield of 3%, which is attractive compared to market averages [8][9]. - The company is diversified across various medical device sectors, but has faced challenges with new product introductions and rising costs affecting profitability; however, new cardiac ablation products have shown nearly 50% revenue growth year-over-year in Q2 of fiscal 2026 [10][11]. - A $500 investment would yield around five shares, while $5,000 would allow for the purchase of 55 shares, providing an opportunity to invest early in a business upturn [11]. Group 3: Omega Healthcare Investors - Omega Healthcare is a REIT focused on senior housing, which faced challenges during the pandemic but maintained its dividend, currently yielding an ultra-high 6.4% [12][13]. - The company has seen a recovery in its core business, with funds from operations rising nearly 8% year-over-year in Q2 of 2025, and is making significant new investments [13][14]. - An investment of $500 would allow for the purchase of approximately 11 shares, while $5,000 would enable the acquisition of 119 shares, indicating strong future potential driven by demographic trends [14]. Group 4: Overall Investment Thesis - Johnson & Johnson, Medtronic, and Omega Healthcare have demonstrated resilience and a commitment to dividends, making them suitable candidates for investors looking to allocate $500 or $5,000 into dividend stocks [15].